Drug Information

Drug General Information
Drug ID
D09GZQ
Former ID
DNC006573
Drug Name
Ac-hPhe-Leu-Gly-LeuVSMe
Drug Type
Small molecular drug
Indication Discovery agent Investigative [528196]
Formula
C28H44N4O6S
Canonical SMILES
CC(C)CC(C=CS(=O)(=O)C)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CCC<br />1=CC=CC=C1)NC(=O)C
InChI
1S/C28H44N4O6S/c1-19(2)16-23(14-15-39(6,37)38)31-26(34)18-29-27(35)25(17-20(3)4)32-28(36)24(30-21(5)33)13-12-22-10-8-7-9-11-22/h7-11,14-15,19-20,23-25H,12-13,16-18H2,1-6H3,(H,29,35)(H,30,33)(H,31,34)(H,32,36)/b15-14+/t23-,24+,25+/m1/s1
InChIKey
NYFDCVWCYDTELB-GNEZGTDISA-N
PubChem Compound ID
11713852
Target and Pathway
Target(s) Cathepsin S Target Info Inhibitor [528196]
KEGG Pathway Lysosome
Phagosome
Antigen processing and presentation
Tuberculosis
NetPath Pathway Leptin Signaling Pathway
IL2 Signaling Pathway
Reactome Endosomal/Vacuolar pathway
Degradation of the extracellular matrix
Trafficking and processing of endosomal TLR
Assembly of collagen fibrils and other multimeric structures
MHC class II antigen presentation
WikiPathways Class I MHC mediated antigen processing & presentation
Trafficking and processing of endosomal TLR
References
Ref 528196J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
Ref 528196J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.